<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathology of malignant liver tumors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathology of malignant liver tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathology of malignant liver tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arief Suriawinata, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1048093835"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary malignant liver tumors resemble and arise from the major constituent cells of the liver, namely hepatocytes (giving rise to hepatocellular carcinoma), biliary epithelial cells (cholangiocarcinoma and biliary cystadenocarcinoma), endothelial cells (angiosarcoma, epithelioid hemangioendothelioma), or combinations of these cells with various mesenchymal cells (eg, hepatoblastoma) [<a href="#rid1">1</a>]. Some (eg, combined hepatocellular-cholangiocellular carcinoma) represent collision of two different tumors or may result from malignant transformation of hepatic progenitor cells with differentiation along two different cell lineages. Secondary liver tumors (ie, metastases from a non-liver primary site) are the most frequent malignant liver tumor, outnumbering primary malignant liver tumors by a large margin (30 to 1 in one series [<a href="#rid1">1</a>]), particularly in patients without underlying liver disease. Furthermore, many now consider primary liver tumors as a continuum, with typical hepatocellular carcinoma and cholangiocarcinoma at the two ends of the spectrum and a range of tumors in between showing variable degrees of hepatocellular and cholangiocarcinoma differentiation, including those with progenitor or stem cell features [<a href="#rid2">2</a>].</p><p>Several premalignant lesions that arise in the liver have been extensively studied in order to better understand both hepatocarcinogenesis and cholangiocarcinogenesis [<a href="#rid3">3,4</a>].</p><p>Premalignant hepatocellular lesions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Dysplastic foci, characterized by cytologic small cell change </p><p class="bulletIndent1"><span class="glyph">●</span>Dysplastic nodules, encompassing low-grade dysplastic nodules and high-grade dysplastic nodules</p><p></p><p>Premalignant biliary lesions are:</p><p class="bulletIndent1"><span class="glyph">●</span>Biliary intraepithelial neoplasia</p><p class="bulletIndent1"><span class="glyph">●</span>Intraductal papillary neoplasm of bile duct</p><p class="bulletIndent1"><span class="glyph">●</span>Mucinous cystic neoplasm (also known as cystadenoma and its malignant counterpart cystadenocarcinoma)</p><p></p><p>This topic review will cover the pathologic appearance of malignant liver tumors, including invasive and premalignant lesions  (<a class="graphic graphic_table graphicRef97463" href="/d/graphic/97463.html" rel="external">table 1</a>). The clinical presentation, diagnosis, and staging of these neoplasms is presented elsewhere.</p><p class="headingAnchor" id="H1048093849"><span class="h1">HEPATOCELLULAR CARCINOMA</span><span class="headingEndMark"> — </span>Hepatocellular carcinoma (HCC) is a primary malignant tumor of the liver with hepatocellular differentiation. HCC commonly develops in patients with chronic liver disease with or without cirrhosis [<a href="#rid5">5</a>]. Cirrhosis itself is the greatest single risk factor for the development of HCC. The incidence of HCC varies geographically according to the different levels of exposure to specific risk factors, such as chronic hepatitis B or C virus infection, exposure to aflatoxin (in resource-limited countries), and alcohol abuse and smoking (in developed countries). Other factors that increase the risk of HCC are nonalcoholic steatohepatitis, hereditary hemochromatosis, and alpha-1-antitrypsin deficiency. Up to 30 percent of HCCs in non-cirrhotic liver appear to arise from hepatic adenomas [<a href="#rid6">6</a>]. Although hepatitis C remains the most common cause of HCC among United States patients for liver transplantation, nonalcoholic steatohepatitis has been increasing steadily over the past two decades as the second most common cause [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/3599.html" rel="external">"Epidemiology and risk factors for hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/d/html/3590.html" rel="external">"Hepatocellular adenoma", section on 'Malignant transformation'</a>.)</p><p class="headingAnchor" id="H1048093856"><span class="h2">Classification</span><span class="headingEndMark"> — </span>The 2019 World Health Organization (WHO) classification categorizes HCC not otherwise specified and several variants (fibrolamellar, scirrhous, clear cell type, steatohepatitic, macrotrabecular, chromophobe, neutrophil rich, and lymphocyte rich) as subtypes of HCC [<a href="#rid8">8</a>]. Hepatoblastoma is categorized separately, and combined hepatocellular-cholangiocarcinoma is classified under malignant biliary tumors [<a href="#rid9">9</a>]. (See <a class="local">'Hepatoblastoma'</a> below and <a class="local">'Combined hepatocellular-cholangiocarcinoma'</a> below.) </p><p>In addition to general WHO tumor type classification, other pathologic descriptions of HCC are often used as well; they are based on degree of differentiation (Edmonson-Steiner grading: well differentiated, moderately differentiated, poorly differentiated, and undifferentiated), morphologic pattern (trabecular, solid, pseudoglandular, scirrhous, inflammatory, steatohepatitic), or cell type (clear cell, small cell, spindle cell, giant cell).</p><p class="headingAnchor" id="H1048093863"><span class="h2">Gross pathology</span><span class="headingEndMark"> — </span>HCC may form a large solitary circumscribed nodule with or without adjacent smaller satellite nodules. In the presence of cirrhosis, HCC may be multinodular within one lobe, which consists of multiple nodules scattered throughout the liver, or may infiltrate the liver diffusely without forming circumscribed nodules (ie, nodular, diffuse, expansive, infiltrative, multifocal, etc) [<a href="#rid10">10-12</a>], but none has proven useful for prognostication or guiding therapy.</p><p>HCCs are usually soft, tan to yellow, often bile-stained, and show areas of necrosis and hemorrhage. Large vessel vascular invasion can be identified on gross examination, and the frequency increases with tumor size. The portal vein and hepatic veins as well as the vena cava may be involved  (<a class="graphic graphic_picture graphicRef97326" href="/d/graphic/97326.html" rel="external">picture 1</a>). Invasion of major bile ducts is an uncommon finding, but when present, it can cause biliary obstruction.</p><p>Small tumors (&lt;5 cm if solitary, or up to three nodules, each smaller than 3 cm) have a better prognosis [<a href="#rid13">13</a>], while the presence of satellite nodules [<a href="#rid14">14</a>] and major vessel invasion are adverse features [<a href="#rid15">15-17</a>]. For patients undergoing tumor resection, the main predictor of poor outcome is incomplete resection [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma"</a>.)</p><p>Necrosis and fibrosis are often observed in tumors that were treated with radiofrequency or microwave ablation or transarterial chemoembolization (TACE). Although imaging studies can differentiate responders and nonresponders, the exact correlation between the extent of necrosis and disease outcome remains unclear, and imaging may overestimate the extent of necrosis [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a> and  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a>.) </p><p class="headingAnchor" id="H1048093870"><span class="h2">Histology</span></p><p class="headingAnchor" id="H73345778"><span class="h3">Hepatocellular carcinoma</span><span class="headingEndMark"> — </span>The cells of HCC resemble hepatocytes in function, cytologic features, and growth patterns. The degree of differentiation reflects the resemblance of tumor cells to normal hepatocytes. When the tumor is less differentiated, the neoplastic cells lose their hepatocyte trait/features or acquire changes seen in other tumors, which presents a diagnostic challenge.</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated HCCs are often small (&lt;2 cm) and composed of cells with mild atypia, arranged in a thin trabecular pattern with rare pseudoglandular structures  (<a class="graphic graphic_picture graphicRef97328" href="/d/graphic/97328.html" rel="external">picture 2</a>). The tumor cells are typically polygonal with granular and eosinophilic cytoplasm  (<a class="graphic graphic_picture graphicRef97328" href="/d/graphic/97328.html" rel="external">picture 2</a>). The tumor cells may secrete bile, an exclusive feature of HCC  (<a class="graphic graphic_picture graphicRef97329" href="/d/graphic/97329.html" rel="external">picture 3</a>), and contain fat  (<a class="graphic graphic_picture graphicRef97330" href="/d/graphic/97330.html" rel="external">picture 4</a>), glycogen  (<a class="graphic graphic_picture graphicRef97331" href="/d/graphic/97331.html" rel="external">picture 5</a>), Mallory-Denk hyalins  (<a class="graphic graphic_picture graphicRef97332" href="/d/graphic/97332.html" rel="external">picture 6</a>), hyalin globules, or fibrinogen  (<a class="graphic graphic_picture graphicRef97334" href="/d/graphic/97334.html" rel="external">picture 7</a>) mimicking or in exaggeration of normal hepatocyte function. A large amount of cytoplasmic fat and/or glycogen causes a clear cell appearance, which may be difficult to distinguish from metastatic clear cell renal cell carcinoma.</p><p></p><p class="bulletIndent1">Most often the tumor grows in a trabecular pattern, with cords of cells separated by vascular sinusoids that are lined by endothelial cells  (<a class="graphic graphic_picture graphicRef97335" href="/d/graphic/97335.html" rel="external">picture 8</a>), mimicking the cell plates and sinusoids of normal liver  (<a class="graphic graphic_picture graphicRef97328" href="/d/graphic/97328.html" rel="external">picture 2</a>). The microtrabecular pattern consists of a thin cord of cells  (<a class="graphic graphic_picture graphicRef122183" href="/d/graphic/122183.html" rel="external">picture 9</a>), and the macrotrabecular pattern is formed by a thick cord of cells  (<a class="graphic graphic_picture graphicRef122184" href="/d/graphic/122184.html" rel="external">picture 10</a>). Expansion of the trabeculae may compress the sinusoids and form a solid or compact pattern of growth. Dilated bile canaliculi, often containing bile and producing a pseudoglandular pattern  (<a class="graphic graphic_picture graphicRef97336" href="/d/graphic/97336.html" rel="external">picture 11</a>), may be seen in the centers of trabeculae. Connective tissue stroma is sparse in typical HCCs, and reticulin fibers are significantly reduced or absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately differentiated HCCs are usually larger tumors (&gt;3 cm), and they are composed of polygonal tumor cells in thick trabecular pattern with frequent pseudoglandular pattern  (<a class="graphic graphic_picture graphicRef97337" href="/d/graphic/97337.html" rel="external">picture 12</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated HCCs are composed of pleomorphic tumor cells in a solid or compact growth pattern  (<a class="graphic graphic_picture graphicRef97338" href="/d/graphic/97338.html" rel="external">picture 13</a>).</p><p></p><p class="headingAnchor" id="H2409297"><span class="h4">Subtypes</span><span class="headingEndMark"> — </span>There are several subtypes of HCC based on the 2019 WHO classification: steatohepatitic, clear cell, macrotrabecular massive, scirrhous, chromophobe, fibrolamellar, neutrophil rich, and lymphocyte rich.</p><p>In addition, there are also other less common histologic subtypes of HCC, such as spindle cell/sarcomatoid, giant cell, undifferentiated, and small cell subtypes. Resected HCCs often have mixed patterns/subtypes, usually trabecular with one or two other subtypes.</p><p class="bulletIndent1"><span class="glyph">●</span>The tumor cells of the steatohepatitic subtype contain fat accompanied by intratumoral inflammation and fibrosis  (<a class="graphic graphic_picture graphicRef122586" href="/d/graphic/122586.html" rel="external">picture 14</a>). This subtype resembles the changes seen in fatty liver disease (steatohepatitis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clear cell subtype is composed of tumor cells with abundant glycogen accumulation, resulting in clear cytoplasm  (<a class="graphic graphic_picture graphicRef122587" href="/d/graphic/122587.html" rel="external">picture 15</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The macrotrabecular massive subtype demonstrates trabeculae &gt;10 cells in thickness  (<a class="graphic graphic_picture graphicRef122588" href="/d/graphic/122588.html" rel="external">picture 16</a>). The macrotrabecular massive subtype has been associated with worse prognosis, large tumor size, high alpha-fetoprotein (AFP) level, satellite nodules, and vascular invasion [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sclerosing or scirrhous subtype [<a href="#rid23">23</a>] is morphologically composed of tumor cells in a background of dense fibrous stroma rather than the sinusoids that are typical for HCC  (<a class="graphic graphic_picture graphicRef97344" href="/d/graphic/97344.html" rel="external">picture 17</a>). This HCC subtype should be differentiated from cholangiocarcinoma, which typically shows abundant dense desmoplastic fibrous stroma. (See <a class="local">'Cholangiocarcinoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fibrolamellar subtype differs clinically, histologically, and molecularly from other HCC subtypes and is discussed in detail below. (See <a class="local">'Fibrolamellar subtype'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The chromophobe subtype resembles the clear cell subtype and histologically mimics chromophobe renal cell carcinoma. The nuclei are predominantly uniform, with scattered single or clusters of anaplastic cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The spindle cell subtype, which has a worse prognosis than conventional HCC [<a href="#rid24">24,25</a>] mimics metastatic sarcoma  (<a class="graphic graphic_picture graphicRef97345" href="/d/graphic/97345.html" rel="external">picture 18</a>), but extensive sampling may yield polygonal hepatoid cells, which are diagnostic of HCC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The giant cell subtype is considered to be a poorly differentiated form of HCC and is composed of large, multinucleated giant cells  (<a class="graphic graphic_picture graphicRef97346" href="/d/graphic/97346.html" rel="external">picture 19</a>). It should be differentiated from metastatic giant cell carcinoma from other organs. (See  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Giant cell carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The inflammatory lymphoepithelioma-like subtype (lymphocyte rich) contains pleomorphic tumor cells in a syncytial growth pattern with a lymphocyte-rich background  (<a class="graphic graphic_picture graphicRef122185" href="/d/graphic/122185.html" rel="external">picture 20</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The small cell subtype often demonstrates neuroendocrine differentiation similar to other small cell neuroendocrine carcinomas arising in other organs; a metastatic small cell carcinoma (usually of lung origin in smokers, but occasionally extrapulmonary) should be in the differential diagnosis. (See  <a class="medical medical_review" href="/d/html/4628.html" rel="external">"Pathobiology and staging of small cell carcinoma of the lung"</a> and  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a> and  <a class="medical medical_review" href="/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p></p><p>Extensive sampling of these uncommon HCC subtypes may demonstrate minor areas of typical HCC. In addition, these special HCC subtypes may lose the HCC-specific antigenicity usually seen in conventional HCC and may not stain with the usual immunohistochemical reagents. (See <a class="local">'Immunohistochemistry'</a> below.)</p><p class="headingAnchor" id="H1048093877"><span class="h3">Dysplastic focus</span><span class="headingEndMark"> — </span>Dysplastic focus is an expansile microscopic focus of hepatocytes with cytologic changes indicative of dysplasia and measuring less than 1 mm [<a href="#rid26">26</a>]. Dysplasia as a premalignant change in hepatocarcinogenesis takes the form of small cell change [<a href="#rid27">27</a>], which is cytologically recognized as hepatocytes with decreased cytoplasmic volume, cytoplasmic basophilia, mild nuclear pleomorphism and hyperchromasia, and increased nuclear cytoplasmic ratio  (<a class="graphic graphic_picture graphicRef97355" href="/d/graphic/97355.html" rel="external">picture 21</a>). According to the original definition, dysplastic focus measures &lt;1 mm in diameter, but this arbitrary size criterion is related to the fact that the microscopic lesions are usually contained within a single cirrhotic nodule [<a href="#rid8">8</a>]. A dysplastic focus is often free of iron deposition (ie, iron-free focus) in a liver with hemochromatosis [<a href="#rid28">28</a>].</p><p>Unlike small cell change, large cell change  (<a class="graphic graphic_picture graphicRef97357" href="/d/graphic/97357.html" rel="external">picture 22</a>) is not directly related to hepatocarcinogenesis (in other words it is not a premalignant lesion), but it has been linked to cellular senescence and it is more prevalent in cirrhotic livers with HCC [<a href="#rid29">29</a>]. Large cell transformation is an important independent risk factor for the subsequent development of HCC, and its presence may be used to identify a subgroup of patients at high risk for HCC requiring more intensive screening [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H1048093884"><span class="h3">Dysplastic nodules</span><span class="headingEndMark"> — </span>Dysplastic nodules are considered preneoplastic lesions, supported by the accumulation of evidence that points to the existence of a sequence of events in dysplastic nodules that precedes the emergence of HCC [<a href="#rid4">4,32</a>]. The evolution of dysplastic nodules into early carcinoma includes induction of an arterial blood supply and stromal invasion [<a href="#rid33">33</a>]. They are usually (but not exclusively) detected in cirrhotic livers. On cut surface, dysplastic nodules bulge and differ from the surrounding cirrhotic liver.</p><p>Dysplastic nodules are classified into low-grade dysplastic nodules (LGDNs) and high-grade dysplastic nodules (HGDNs) based on cytologic and architectural atypia as seen on microscopic examination:</p><p class="bulletIndent1"><span class="glyph">●</span>In LGDN, the hepatocytes rarely show a clonal population, and there is minimal nuclear atypia and only a slight increase in the nuclear:cytoplasmic ratio. Large cell change is often present, but mitotic figures are absent. Without obvious clonal population, the distinction between LGDN and a large regenerative nodule is difficult and does not carry any practical consequences as long as the nodules lack the features of HGDN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HGDN shows cytologic and/or architectural atypia but is insufficient for the diagnosis of HCC. Small cell change and architectural atypia, such as thick plates (up to three cells thick) and occasional pseudoglandular structures, are common in HGDN. In needle biopsies, the differential diagnosis between HGDN and well-differentiated HCC may be difficult or impossible. The vascular supply of dysplastic nodules is altered, particularly in HGDN, where unpaired arteries can occasionally be found with increase of sinusoidal capillarization beyond the vicinity of portal tracts as demonstrated by immunostaining for CD31 or CD34. (See <a class="local">'Immunohistochemistry'</a> below.)</p><p></p><p class="bulletIndent1">A combination of glypican-3 (GPC3), heat shock protein 70 (HSP-70), and glutamine synthetase immunostaining may aid the distinction between HGDNs and HCCs. (See <a class="local">'Immunohistochemistry'</a> below.) </p><p></p><p class="headingAnchor" id="H1048093891"><span class="h3">Small and early hepatocellular carcinoma</span><span class="headingEndMark"> — </span>Small HCCs up to 2 cm in diameter are classified into distinctly nodular type and vaguely nodular type. Distinctly nodular HCCs (also known as progressed HCCs) are mostly moderately differentiated, lack portal tracts, and show evidence of microvascular invasion. Vaguely nodular HCCs (also known as early HCCs or small HCC with indistinct margins) retain the basic architecture of the background cirrhotic liver, and the neoplastic cells grow in and replace the nonneoplastic liver cords. The small neoplastic cells (reminiscent of small cell change) are arranged in irregular, thin trabeculae with pseudoglandular structures or fatty changes. They grow around preexisting portal tracts and/or invade the portal tracts (stromal invasion). A fibrous capsule is lacking, and the tumor contains "entrapped" portal tracts  (<a class="graphic graphic_picture graphicRef97360" href="/d/graphic/97360.html" rel="external">picture 23</a>).</p><p>Most vaguely nodular HCCs are well-differentiated HCCs. Most of these nodules are clinically hypovascular because of the insufficient development of unpaired tumor arteries and incomplete sinusoidal capillarization. Distinctly nodular HCC or progressed HCC is biologically more advanced and usually of higher grade, and there are typical HCC features and well-developed unpaired tumor arteries, which facilitate their detection by contrast enhanced imaging methods. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Computed tomography'</a>.) </p><p>Small nodules with a "nodule-in-nodule" appearance are either HGDN with a subnodule of HCC, or a well-differentiated HCC with a subnodule of moderately differentiated HCC. Radiologically, these are detected as hypovascular nodules containing a hypervascular focus on contrast images, which indicates malignancy [<a href="#rid34">34</a>]. Nodule-in-nodule HCC is considered to be evidence of multistep hepatocarcinogenesis [<a href="#rid35">35</a>], where the inner, less-well-differentiated subnodule progressively overtakes the outer, better differentiated component of the tumor.</p><p>Stromal invasion, as an important criterion of a carcinoma, is easier to identify in distinctly nodular HCC but is obscured in the vaguely nodular type. The absence of cytokeratin (CK)7-positive duct staining is a feature of areas of stromal invasion in small HCC and can be helpful in distinguishing small HCCs from minimally invasive HCCs of the vaguely nodular type, and overtly invasive HCCs of the distinctly nodular type. (See <a class="local">'Immunohistochemistry'</a> below.) </p><p class="headingAnchor" id="H73345470"><span class="h3">Immunohistochemistry</span><span class="headingEndMark"> — </span>Immunohistochemistry can aid in the diagnosis and differential diagnosis. In well-differentiated and moderately differentiated tumors, the trabeculae are lined directly by CD34 or CD31-positive endothelial cells  (<a class="graphic graphic_picture graphicRef97339" href="/d/graphic/97339.html" rel="external">picture 24</a>). The presence of bile canaliculi may be highlighted by polyclonal carcinoembryonic antigen (pCEA) or CD10  (<a class="graphic graphic_picture graphicRef97340" href="/d/graphic/97340.html" rel="external">picture 25</a>) [<a href="#rid36">36,37</a>]. The canalicular pattern of staining for pCEA or CD10 indicates hepatocellular differentiation and is diagnostic of HCC. The tumor cells may also contain AFP or alpha-1-antitrypsin or fibrinogen that can be demonstrated by immunohistochemical staining. However, high serum levels of the tumor marker AFP do not correlate with positive AFP immunostaining. AFP immunostaining is positive in fewer than 40 percent of HCCs [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Alpha-fetoprotein'</a>.)</p><p>Immunohistochemically, most well- to moderately well-differentiated HCC's are positive for hepatocyte paraffin 1 (HepPar1)  (<a class="graphic graphic_picture graphicRef97341" href="/d/graphic/97341.html" rel="external">picture 26</a>), arginase-1, bile salt export pump transporter, cytoplasmic thyroid transcription factor-1 (TTF1)  (<a class="graphic graphic_picture graphicRef97343" href="/d/graphic/97343.html" rel="external">picture 27</a>), glutamine synthetase, GPC3, and CK8 and 18 [<a href="#rid38">38-43</a>]. Arginase-1 is the most sensitive marker for all levels of differentiations of HCC, while glypican-3 is highly sensitive for poorly differentiated tumors [<a href="#rid43">43</a>]. The combination use of arginase-1 and glypican-3 enables identification of nearly all cases of poorly differentiated HCC.</p><p>Fewer than 5 percent of HCCs may be positive for CDX2 [<a href="#rid44">44</a>]; therefore, aberrant CDX2 expression in a liver tumor does not completely exclude a diagnosis of HCC.</p><p>Immunostaining with a combination of GPC3, HSP-70, and glutamine synthetase may aid the distinction between HGDNs and HCCs [<a href="#rid41">41,45</a>]. At least two diffusely positive stains out of the three markers are seen in early or well-differentiated HCC. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Clinical practice guidelines'</a>.)</p><p>Stromal invasion, as an important criterion of a carcinoma, is easier to identify in distinctly nodular HCC but is obscured in the vaguely nodular type. The absence of CK7-positive ductular reaction is a feature of areas of stromal invasion in small HCC and can be helpful in distinguishing small HCCs from dysplastic nodules, minimally invasive HCCs of the vaguely nodular type, and overtly invasive HCCs of the distinctly nodular type [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/3575.html" rel="external">"Approach to the adult patient with an incidental solid liver lesion"</a>.)</p><p>CK19 staining is a surrogate marker for progenitor cell origin, and its positivity in HCC (&gt;5 percent) indicates activation of the epidermal growth factor signaling pathway, which correlates with aggressive behavior, microvascular invasion, fibrous stroma, less tumor-capsule formation, the presence of lymph node and extrahepatic metastasis, early relapse, and poor disease-free survival [<a href="#rid47">47-50</a>]. Other progenitor cell markers, EpCam, SALL4, and CD56, are often used in combination with CK19 in the investigation of the progenitor cell component or the so-called "stemness" feature of HCC.</p><p>In addition to necrosis and fibrosis, increased expression of CK19 and areas of biliary differentiation ("progenitor cell phenotype") often occur after chemoembolization treatment [<a href="#rid51">51,52</a>].</p><p>Endothelial cell-specific molecule 1 (ESM1) is overexpressed in many macrotrabecular massive HCCs; therefore, ESM1 immunostaining of sinusoidal stromal cells surrounding trabeculae helps to identify macrotrabecular architecture in HCC [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H3036988112"><span class="h3">Molecular classification</span><span class="headingEndMark"> — </span>Progress in HCC gene profiling over the past several years has revealed frequent mutations and chromosome alterations in multiple genes including the telomerase reverse transcriptase (<em>TERT)</em> promoter, beta-1 catenin (<em>CTNNB1</em>), <em>TP53</em>, axis inhibitor-1 (<em>AXIN1</em>), AT-rich interaction domain-containing protein 1A (<em>ARID1A</em>), nuclear factor erythroid 2-like 2 (<em>NFE2L2</em>), <em>ARID2</em>, tuberous sclerosis 1 (<em>TSC1</em>), <em>TSC2</em>, and ribosomal protein S6 kinase 90-kD 3 (RPS6KA3) [<a href="#rid54">54-58</a>]. <em>CTNNB1</em> and <em>TP53</em> mutations are mutually exclusive. Although the histologic and molecular features of HCCs are very heterogenous, there are several histologic subtypes of HCCs that are known to harbor specific genetic alterations [<a href="#rid56">56</a>] (see <a class="local">'Hepatocellular carcinoma'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><em>TERT</em> promoter mutation is the most common somatic mutation in approximately 40 to 65 percent of HCCs.</p><p></p><p class="bulletIndent1">Patients with <em>TERT</em> promotion are older and are more likely to be hepatitis C virus (HCV) positive or have a history of alcoholism.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HCCs in patients with aflatoxin B1 exposure and/or who are hepatitis B virus (HBV) positive commonly show <em>TP53</em>, <em>ERFF1</em>, and nuclear receptor corepressor (<em>NCOR</em>) 1 mutations. <em>NCOR</em> mutations function as a suppressor of beta catenin expression [<a href="#rid57">57</a>]. <em>TERT</em> promoter mutation is only seen in fewer than 10 percent of these HCCs due to recurrent integration of HBV into the <em>TERT</em> promoter [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HCCs in HCV-positive patients more commonly show <em>TERT </em>promoter mutations, <em>CTNNB1</em> mutations, and cyclin-dependent kinase inhibitor 2A (<em>CDKN2A</em>) silencing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated, often cholestatic, HCCs are associated with <em>CTNNB1</em> mutation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated  (<a class="graphic graphic_picture graphicRef97338" href="/d/graphic/97338.html" rel="external">picture 13</a>), highly proliferative, and macrotrabecular-massive  (<a class="graphic graphic_picture graphicRef122184" href="/d/graphic/122184.html" rel="external">picture 10</a>) HCCs often harbor <em>TP3</em> mutations and fibroblast growth factor 19 (<em>FGF19</em>) amplification.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scirrhous HCC is characterized by <em>TSC1</em>/<em>TSC2</em> mutations and an increase in transforming growth factor beta (<em>TGFB</em>) signaling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Steatohepatitic HCCs show frequent <em>IL-6/JAK/STAT</em> activation without <em>CTNNB1</em> and <em>TP53</em> pathway alterations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors with the progenitor/stem cell phenotype commonly harbor <em>RP6SKA3</em> and <em>TP53 </em>mutations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isocitrate dehydrogenase (<em>IDH</em>) 1/2 mutations are more frequent in intrahepatic cholangiocarcinomas than in HCCs. HCCs with <em>IDH</em> mutations are associated with poor prognosis. <em>IDH</em> mutations indicate a shift toward the biliary phenotype, even when tumors do not show mixed morphology or have progenitor/stem cell features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HCCs belonging to the "immune-specific class" demonstrate molecular features resembling those of tumors most responsive to immunotherapy, such as high infiltration of immune cells, expression of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), and active interferon gamma signaling [<a href="#rid60">60</a>]. PD-L1 immunostaining, however, does not correlate well with immune-class HCC and cannot be used to predict response to immunotherapy [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'Checkpoint inhibitor immunotherapy'</a>.)</p><p></p><p class="headingAnchor" id="H1048093898"><span class="h2">Fibrolamellar subtype</span><span class="headingEndMark"> — </span>Fibrolamellar carcinoma is a distinctive HCC subtype that differs clinically, histologically, and molecularly from other HCC subtypes [<a href="#rid62">62-64</a>]. It affects younger individuals 5 to 35 years of age. In contrast to conventional HCC, it does not show male predominance, involving both sexes equally, and is not associated with cirrhosis or chronic viral hepatitis. In general, fibrolamellar carcinoma has better prognosis than conventional HCC. Patients present with abdominal mass or pain. Serum AFP levels are normal in 90 percent of cases. (See  <a class="medical medical_review" href="/d/html/16571.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of fibrolamellar carcinoma"</a>.)</p><p>Grossly fibrolamellar carcinoma commonly forms a solitary, large, firm, well-circumscribed tumor, which may be encapsulated. The cut surface demonstrates gray-white fibrous bands, which subdivide the tumor into smaller nodules resembling focal nodular hyperplasia.</p><p>Histologically, fibrolamellar carcinoma consists of large polygonal tumor cells with eosinophilic granular cytoplasm, large vesicular nuclei, and prominent nucleoli  (<a class="graphic graphic_picture graphicRef97362" href="/d/graphic/97362.html" rel="external">picture 28</a>). The cytoplasmic eosinophilia and granularity are due to abundant mitochondria. The cells are separated into various-sized clusters by parallel lamellae of hyaline/hypocellular fibrous tissue. Fibrinogen-containing tumor cells with "pale inclusions" or "hyaline bodies" are often present, similar to conventional HCC. Pseudoglandular areas are occasionally present and may contain bile or mucin-like material  (<a class="graphic graphic_picture graphicRef97363" href="/d/graphic/97363.html" rel="external">picture 29</a>), which can be mistaken for combined hepatocellular-cholangiocarcinoma. (See <a class="local">'Combined hepatocellular-cholangiocarcinoma'</a> below.)</p><p>The immunohistochemical profile is similar to that of HCC, such as positive staining for HepPar1, GPC3, arginase-1, and pCEA, and CD10 positivity. However, immunostaining for CK7 and epithelial membrane antigen (EMA) is positive in fibrolamellar carcinoma only, suggesting possible dual cholangiocyte and hepatocyte differentiation of this tumor [<a href="#rid65">65</a>]. Immunostain for CD68 is also specific for fibrolamellar carcinoma; its expression is associated with the <em>CD68</em> gene that encodes a transmembrane glycoprotein located within lysosomes and endosomes [<a href="#rid66">66</a>]. Although fibrolamellar carcinomas have a similar fibrogenic property to scirrhous HCC, only fewer than 40 percent of fibrolamellar carcinomas express progenitor cell markers such as CK19 and EpCam [<a href="#rid67">67,68</a>]. (See <a class="local">'Immunohistochemistry'</a> above.)</p><p class="headingAnchor" id="H283932055"><span class="h3">Molecular pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis remains largely unknown. However, a recurrent unique fusion gene between <em>DNAJB1</em> (DnaJ/HSP40 homolog, subfamily B, member 1) and <em>PRKACA</em> (protein kinase, cAMP-dependent, catalytic, alpha), <em>DNAJB1-PRKACA</em>, has been reported in fibrolamellar carcinomas but not in other HCC variants or cholangiocellular tumors [<a href="#rid64">64,69,70</a>]. Preliminary data suggest that the fusion protein plays a transformative role, although its role in pathogenesis is not conclusively established [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H1048093912"><span class="h1">CHOLANGIOCARCINOMA</span><span class="headingEndMark"> — </span>A cholangiocarcinoma (CC) is an adenocarcinoma arising from biliary epithelium. CCs may occur anywhere along the biliary tree from small bile ducts, bile ductules, and remnants of ductal plate in the liver (intrahepatic CC) to large hilar and extrahepatic bile ducts (extrahepatic CC) [<a href="#rid71">71</a>]. A Klatskin tumor is an extrahepatic CC that arises at the common hepatic duct bifurcation. (See  <a class="medical medical_review" href="/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma", section on 'Bismuth-Corlette classification for perihilar tumors'</a>.)</p><p>A distinction is made between intrahepatic and extrahepatic CC not only because of differences in anatomic location, but also because they have distinct risk factors, clinical presentation, therapy, and epidemiology. Therefore, the term "cholangiocarcinoma" has been proposed exclusively for intrahepatic tumors, and the term "bile duct carcinoma" for tumors arising from large bile ducts both at the hilum and along the extrahepatic biliary tree. However, this terminology is not uniformly utilized. (See  <a class="medical medical_review" href="/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma"</a>.)</p><p>Intrahepatic CCs account for fewer than 20 percent of CCs. In the majority of cases, no underlying liver disease is identified, although some epidemiologic studies suggest chronic (HCV) infection as a major risk factor for intrahepatic CC. It remains unclear how HCV is involved in cholangiocarcinogenesis. (See  <a class="medical medical_review" href="/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma", section on 'Viral hepatitis'</a>.)</p><p>Biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm of bile duct (IPNB) are considered to be in situ lesions in the multistep progression of cholangiocarcinogenesis.</p><p class="headingAnchor" id="H1048093919"><span class="h2">Gross pathology</span><span class="headingEndMark"> — </span>There are differences in gross morphology and microscopic features of intrahepatic and extrahepatic CCs. Intrahepatic CCs are divided on the basis of morphologic appearance into mass forming, periductal infiltrating, and intraductal subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span>Mass forming intrahepatic CCs are multilobulated, unencapsulated, firm, white-gray tumors, owing to extensive desmoplastic stroma. The morphologic appearance is that of a sclerosing or scirrhous adenocarcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The periductal infiltrating subtype shows extensive infiltration along intrahepatic portal structures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The intraductal subtype is confined within large bile ducts often with papillary architecture. The intraductal subtype is now referred to as IPNB and considered to be an in situ lesion. (See <a class="local">'Intraductal papillary neoplasm of bile duct'</a> below.)</p><p></p><p>In contrast, extrahepatic CCs typically form ill-defined, infiltrating, firm lesions in the hepatic hilum or along the extrahepatic bile duct.</p><p class="headingAnchor" id="H1048093926"><span class="h2">Histology and immunohistochemistry</span><span class="headingEndMark"> — </span>Intrahepatic CCs are usually well to moderately differentiated adenocarcinomas, classically consisting of small well-differentiated uniform neoplastic glands, or larger elongated or tortuous glands composed of cuboidal neoplastic cells, or nests of cribriform structures (comedocarcinoma-like) made up of small cells with scant cytoplasm and dark nuclei  (<a class="graphic graphic_picture graphicRef97382" href="/d/graphic/97382.html" rel="external">picture 30</a>). The tumors are often highly cellular at the periphery with a hypocellular densely fibrotic center. The tumor cells insinuate the sinusoids and not the trabecular cords at the border of the lesion.</p><p>Other non-classic microscopic types that can be encountered are the trabecular and hilar types and cholangiolocellular carcinoma (CCC). The trabecular type of intrahepatic CC is characterized by polygonal cells with eosinophilic cytoplasm that are arranged in anastomosing trabeculae. The hilar type shows features resembling extrahepatic CC. Cholangiolocellular type is described below. (See <a class="local">'Cholangiolocellular carcinoma'</a> below.)</p><p>Molecular analysis on intrahepatic CC has revealed two histologic subtypes (large duct type  (<a class="graphic graphic_picture graphicRef122187" href="/d/graphic/122187.html" rel="external">picture 31</a>) and small duct type  (<a class="graphic graphic_picture graphicRef122188" href="/d/graphic/122188.html" rel="external">picture 32</a>)) that are associated with distinct clinical and molecular features [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large duct type frequently harbors <em>KRAS</em> mutation, affects the perihilar region, and is characterized by infiltrating neoplastic ductular structures with columnar cell lining and abundant mucin production. Large duct type is also associated with perineural invasion, lymph node metastasis, high carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) levels, and poor prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small duct type is frequently associated with isocitrate dehydrogenase (<em>IDH</em>) 1/2 mutation and fibroblast growth factor receptor 2 (<em>FGFR2</em>) translocation, is peripherally located, and is characterized by small ductular structures with a mucin-poor cuboidal cell lining. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large duct type is positive for S100P+, and small duct type is positive for N-cadherin and natural cell adhesion molecule (NCAM, also known as CD56) immunohistochemistry.</p><p></p><p>Immunohistochemistry can be very helpful for the differential diagnosis, which includes primary hepatocellular carcinoma (HCC) and metastatic adenocarcinoma  (<a class="graphic graphic_table graphicRef97387" href="/d/graphic/97387.html" rel="external">table 2</a>) [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunohistochemically, almost all CCs show strong positivity for cytokeratin (CK)7 and CK19. Among common adenocarcinomas, CK7 positivity is consistent with biliary tract origin  (<a class="graphic graphic_table graphicRef58475" href="/d/graphic/58475.html" rel="external">table 3</a>). However, metastatic cancers of the lung and breast are also CK7 positive, and the diagnosis of a CC may be a diagnosis of exclusion. Positivity for CK20 can be seen in up to 20 percent of cases of intrahepatic CC. Immunostaining for monoclonal carcinoembryonic antigen (mCEA) is diffusely positive in up to 75 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunohistochemically, most well to moderately well-differentiated HCCs are positive for hepatocyte paraffin 1 (HepPar1), arginase-1 [<a href="#rid74">74</a>], cytoplasmic thyroid transcription factor-1 (TTF1), glutamine synthetase, glypican-3 (GPC3), and CK 8 and 18. (See <a class="local">'Immunohistochemistry'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An antibody panel consisting of Hep Par1, arginase-1, mCEA, CK7, CK20, TTF-1 (positive cytoplasmic staining in HCC, positive nuclear staining in lung adenocarcinoma), and CDX2 (positive nuclear staining in intestinal adenocarcinoma) could be used to optimize the differential diagnosis of HCC, metastatic adenocarcinoma, and CC [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H1048093933"><span class="h2">Cholangiolocellular carcinoma</span><span class="headingEndMark"> — </span>CCC is a distinct subtype of intrahepatic CC, thought to originate from the ductules and/or canals of Hering, where hepatic progenitor cells (HPCs) reside [<a href="#rid71">71,76</a>]. HPCs can differentiate into hepatocytes and cholangiocytes and can, on their way to differentiation, give rise to tumors with a whole range of phenotypes that have varying hepatocellular and cholangiocellular differentiation characteristics. The molecular signature of stemness in combined hepatocellular-cholangiocarcinoma has supported the concept of a stem/progenitor cell origin of combined hepatocellular-cholangiocarcinoma. CCC has been reported to be associated with HCV infection [<a href="#rid77">77,78</a>].</p><p>Histologically, there are two or three different histologic areas within the tumor (CCC, HCC, and/or CC), but CCC is the predominant component (&gt;80 percent). It is composed of mixtures of small monotonous glands in antler-like anastomosing patterns with an abundant hyalinized and/or edematous fibrous stroma with lymphocytic infiltration  (<a class="graphic graphic_picture graphicRef97389" href="/d/graphic/97389.html" rel="external">picture 33</a>) [<a href="#rid79">79,80</a>]. The tumor cells are cuboidal, smaller in size than normal hepatocytes, with scant eosinophilic cytoplasm, round or oval nuclei, and indistinct nucleoli, mimicking a benign ductular reaction  (<a class="graphic graphic_picture graphicRef122189" href="/d/graphic/122189.html" rel="external">picture 34</a>) [<a href="#rid79">79</a>]. The CCC area is CK7, CK19, NCAM (CD56), and EpCam positive. The HCC area is usually located at the interface to the nonneoplastic liver parenchyma and has a trabecular growth pattern with canalicular staining for pCEA and CD10, immunohistochemically positive for HepPar-1. The CC area is usually small with papillary and/or clear glandular formation, mucin production, and abundant fibrous stroma; it is immunohistochemically positive for CK7, CK19, and cytoplasmic pCEA immunostaining.</p><p>NCAM (CD56), a marker of progenitor cell, is useful in differentiating CCC from classical well-differentiated intrahepatic CC, which commonly does not express this marker. It should be noted, however, that NCAM is also positive in ductular reaction and bile duct adenoma.</p><p>More recently, molecular analysis revealed that CCC has a distinct biliary molecular profile with low chromosomal instability, enrichment of transforming growth factor beta (<em>TGFB</em>), and immune-related signaling [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H73346145"><span class="h2">Combined hepatocellular-cholangiocarcinoma</span><span class="headingEndMark"> — </span>The 2019 World Health Organization (WHO) classification of tumors defines combined hepatocellular-cholangiocarcinoma as a primary liver carcinoma with the unequivocal presence of both hepatocytic and cholangiocytic differentiation within the same tumor that does not include collision tumors  (<a class="graphic graphic_picture graphicRef122190" href="/d/graphic/122190.html" rel="external">picture 35</a>) [<a href="#rid9">9</a>]. This tumor is distinguished from separate or multifocal HCC and CC arising in the same liver lobe (which may be separated or intermixed "collision" tumors). The combined hepatocellular-cholangiocarcinoma is thought to result from malignant transformation of a common hepatic progenitor cell with differentiation along two different cell lineages [<a href="#rid71">71,82</a>].</p><p>Combined hepatocellular-cholangiocarcinoma, also referred to as primary liver carcinoma with biphenotypic differentiation, is now acknowledged as a distinct subtype of CC [<a href="#rid9">9,83,84</a>]. They comprise &lt;1 percent of all primary liver carcinomas and are staged and treated as intrahepatic CCs. Combined hepatocellular-cholangiocarcinomas occur in cirrhotic and noncirrhotic livers. (See  <a class="medical medical_review" href="/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma", section on 'Combined hepatocellular-cholangiocarcinoma'</a>.)</p><p>The gross morphology of this tumor is not significantly different from that of HCC. Tumors with abundant fibrous stroma associated with the CC component may have firm and fibrotic cut surface. The HCC component may be well, moderately, or poorly differentiated. Confirmation of HCC differentiation is easily provided by immunohistochemical staining. Histologically, combined hepatocellular-cholangiocarcinoma must be distinguished from the pseudoglandular type of HCC  (<a class="graphic graphic_picture graphicRef97336" href="/d/graphic/97336.html" rel="external">picture 11</a>). The biliary component is usually a typical adenocarcinoma; well, moderately, or poorly differentiated; and often accompanied by abundant stroma. The cholangiocellular component is positive for CK7 and 19, epithelial membrane antigen, and mCEA. There are no published consensus guidelines for the minimum amount of HCC or CC to qualify for the diagnosis.</p><p>In 2018, an international consensus group recommended that the diagnosis of combined hepatocellular-cholangiocarcinoma be based primarily on routine histopathology with hematoxylin and eosin staining [<a href="#rid85">85</a>]. Immunostains can be used for confirmation only and are not essential for diagnosis. If stem/progenitor cell, intermediate cell, and/or CCC components are observed, they are noted in a comment as a feature rather than a formal diagnostic subtype.</p><p class="headingAnchor" id="H150450565"><span class="h2">Precursor (intraductal) lesions</span><span class="headingEndMark"> — </span>There are three known precursors to invasive CC: IPNB, the rare intraductal tubulopapillary neoplasm of bile duct (ITPN), and the much more common BilIN. Conversion from normal to malignant bile epithelium through one of these precursor lesions probably requires a stepwise accumulation of successive genetic abnormalities [<a href="#rid86">86</a>], similar to the sequence of events that underlies colorectal carcinogenesis, although the level of understanding of molecular pathogenesis of CC is significantly less than that for other gastrointestinal cancers. (See  <a class="medical medical_review" href="/d/html/663.html" rel="external">"Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma", section on 'Molecular pathogenesis'</a>.)</p><p class="headingAnchor" id="H1048093940"><span class="h3">Biliary intraepithelial neoplasia</span><span class="headingEndMark"> — </span>The term BilIN applies to microscopic flat or low-papillary dysplastic epithelium, known previously as biliary dysplasia, atypical biliary epithelium, or carcinoma in situ [<a href="#rid87">87</a>]. Biliary intraepithelial neoplasia occurs more often in hepatolithiasis, choledochal cysts, and primary sclerosing cholangitis [<a href="#rid88">88</a>]. BilIN is classified into three grades based on the degree of cytologic and structural atypia: BilIN-1 (low-grade dysplasia), BilIN-2 (intermediate-grade dysplasia), and BilIN-3 (high-grade dysplasia)  (<a class="graphic graphic_picture graphicRef98058" href="/d/graphic/98058.html" rel="external">picture 36</a>) [<a href="#rid87">87,89,90</a>].</p><p>BilIN can be flat, micropapillary, or pseudopapillary. Cytologic atypia ranges from mild with increased nuclear to cytoplasmic ratio in BilIN-1, to severe with marked nuclear hyperchromasia and polymorphism, diffuse loss of polarity, resembling carcinoma without invasion in BilIN-3.</p><p class="headingAnchor" id="H1048093947"><span class="h3">Intraductal papillary neoplasm of bile duct</span><span class="headingEndMark"> — </span>The IPNB is characterized by a markedly dilated and cystic biliary system and multifocal papillary epithelial lesions with or without mucin production  (<a class="graphic graphic_picture graphicRef97392" href="/d/graphic/97392.html" rel="external">picture 37</a>). This rare type of tumor resembles its counterpart: the intraductal papillary mucinous neoplasm (IPMN) of the pancreas [<a href="#rid91">91-94</a>]. (See  <a class="medical medical_review" href="/d/html/2510.html" rel="external">"Pathology of exocrine pancreatic neoplasms", section on 'Intraductal papillary mucinous neoplasms'</a> and  <a class="medical medical_review" href="/d/html/5637.html" rel="external">"Classification of pancreatic cysts", section on 'Intraductal papillary mucinous neoplasms'</a>.)</p><p>Several histologic types of IPNBs have been recognized based on their having neoplastic epithelium similar to IPMN of the pancreas (ie, pancreatobiliary, intestinal, and gastric foveolar types and the rare oncocytic type) [<a href="#rid93">93,95</a>]. More recently, two general categories of IPNBs have been proposed based on histologic similarities to their counterpart in the pancreas: type 1 IPNBs, which share many features with IPMNs of the pancreas, and type 2 IPNBs, which are variably different from IPMNs of the pancreas [<a href="#rid94">94,96,97</a>]. Type 1 IPNBs are characterized by villous architecture with thin fibrovascular cores and frequent mucin production, while type 2 IPNBs have complex papillary, polypoid, tubular, solid, or cribriform intraductal structures. Type 1 IPNBs of any subtype develop in the intrahepatic bile ducts, while type 2 IPNBs develop in the extrahepatic bile duct. These findings suggest that IPNBs arising in the intrahepatic ducts are biliary counterparts of IPMNs of the pancreas, while those arising in the extrahepatic ducts display differences from prototypical IPMNs of the pancreas. </p><p>IPNB is associated with two types of invasive tumors: tubular carcinoma and mucinous/colloid carcinoma [<a href="#rid91">91</a>]. Tubular carcinoma is usually associated with pancreatobiliary type of IPNB, whereas mucinous/colloid carcinoma is usually associated with intestinal type of IPNB. Patients with invasive tubular carcinoma carry a worse prognosis than mucinous/colloid carcinoma or IPNB alone [<a href="#rid95">95</a>].</p><p>IPNB is classified into two grades based on the highest degree of cytologic and structural atypia: low-grade and high-grade intraepithelial neoplasia [<a href="#rid97">97</a>]. The criteria of classification are similar to those of IPMNs of the pancreas. When an invasive carcinoma is present, it should be designated as IPNB with an associated invasive carcinoma and staged similar to CC.</p><p class="headingAnchor" id="H3812500079"><span class="h3">Intraductal tubulopapillary neoplasm of bile duct</span><span class="headingEndMark"> — </span>The ITPN is a rare intraductal polypoid neoplasm composed of densely packed tubular glands with high-grade dysplasia, solid areas, or abortive papillae  (<a class="graphic graphic_picture graphicRef114106" href="/d/graphic/114106.html" rel="external">picture 38</a>) [<a href="#rid97">97,98</a>]. Necrosis in a "comedo-carcinoma"-like pattern is common. Invasive tubular carcinoma is frequently seen in ITPN (up to 90 percent of ITPN cases). </p><p class="headingAnchor" id="H1048093954"><span class="h1">MUCINOUS CYSTIC NEOPLASMS (BILIARY CYSTADENOMA AND CYSTADENOCARCINOMA)</span><span class="headingEndMark"> — </span>The term mucinous cystic neoplasm of the liver (MCN) encompasses cystic tumors previously referred to as biliary cystadenoma and cystadenocarcinoma. The 2019 World Health Organization (WHO) classification of tumors of the digestive tract categorizes MCNs based on the highest degree of cytoarchitectural atypia (ie, with low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia, or an associated invasive carcinoma [<a href="#rid99">99</a>]). Imaging studies of MCN usually disclose a solitary, multiloculated, cystic structure, which on angiography is avascular and displaces the surrounding vessels [<a href="#rid100">100</a>]. MCN does not connect to the biliary tree. Thickening of internal septation and the presence of mural nodule should raise the suspicion of MCN with high-grade intraepithelial neoplasia. The term "cystadenocarcinoma" has been used to designate MCN with high-grade intraepithelial neoplasia, and it has also been used to designate MCN with an associated invasive carcinoma. The 2019 WHO classification recommends that the terms "MCN with high-grade intraepithelial neoplasia" and "MCN with an associated invasive carcinoma" be preferentially utilized [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H1048093961"><span class="h2">Gross pathology</span><span class="headingEndMark"> — </span>MCNs can measure up to 30 cm. The shape depends on the complexity of internal septation and the number of cysts. The content of the cysts varies from clear thin to thick mucoid fluid. Dark blood-tinged fluid or necrotic material may be found in either traumatized MCN or high-grade MCN, whereas purulent mucoid material is often seen in infected cyst. Mural nodules are common in high-grade MCNs.</p><p class="headingAnchor" id="H1048093968"><span class="h2">Histology</span><span class="headingEndMark"> — </span>The epithelial lining varies from a single layer of columnar, cuboidal, or flattened mucinous epithelium in low-grade MCNs, to pleomorphic malignant cells with tubulopapillary growth pattern that may invade the stroma and capsule in high-grade MCNs  (<a class="graphic graphic_picture graphicRef97393" href="/d/graphic/97393.html" rel="external">picture 39</a>). Areas of transition from benign epithelial lining to malignant cells may be found. The underlying dense fibrous, hyalinized, or cellular "ovarian-like" stroma is characteristic of these lesions, often requiring extensive sampling to demonstrate its presence. The cellular "ovarian-like" stroma is seen only in female patients and is positive for estrogen and progesterone receptors by immunostaining [<a href="#rid101">101</a>].</p><p>If there is a component of invasive adenocarcinoma, the lesions should be designated as MCN with an associated invasive carcinoma. Most associated invasive components are ductal adenocarcinomas, often requiring extensive sampling to identify the foci of invasion. (See  <a class="medical medical_review" href="/d/html/3588.html" rel="external">"Diagnosis and management of cystic lesions of the liver", section on 'Mucinous cystic neoplasm with associated invasive carcinoma (cystadenocarcinoma)'</a>.)</p><p class="headingAnchor" id="H1048093975"><span class="h1">HEPATOBLASTOMA</span><span class="headingEndMark"> — </span>Hepatoblastoma is the most common primary hepatic malignancy in early childhood. The majority of hepatoblastomas occur in the first two years of life and rarely in children older than five years. This is in contrast to hepatocellular carcinoma (HCC), which rarely occurs in children younger than five years old. The incidence of hepatoblastoma in boys is twice that in girls. Syndromes with an increased incidence of hepatoblastoma include Beckwith Wiedmann syndrome, trisomy 18, trisomy 21, Aicardi syndrome, Li-Fraumeni syndrome, Goldenhar syndrome (a type of craniofacial microsomia), type 1a glycogen storage disease (von Gierke disease), and familial adenomatous polyposis (FAP) [<a href="#rid102">102,103</a>]. (See  <a class="medical medical_review" href="/d/html/13555.html" rel="external">"Beckwith-Wiedemann syndrome", section on 'Neoplasia'</a> and  <a class="medical medical_review" href="/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 18 syndrome'</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities", section on 'Trisomy 21 (Down syndrome)'</a> and  <a class="medical medical_review" href="/d/html/2926.html" rel="external">"Syndromes with craniofacial abnormalities"</a> and  <a class="medical medical_review" href="/d/html/14255.html" rel="external">"Li-Fraumeni syndrome"</a>.)</p><p>Hepatoblastomas commonly occur as a single mass in up to 85 percent of cases and more often in the right lobe of the liver. Because of rapid growth, death can occur from rupture and hemorrhage. Serum alpha-fetoprotein (AFP) levels are markedly elevated. Sexual precocity may be present due to the synthesis of ectopic gonadotropin. (See  <a class="medical medical_review" href="/d/html/7466.html" rel="external">"Epidemiology, pathophysiology, and causes of gynecomastia", section on 'Other rare causes'</a>.)</p><p>In children, hepatoblastoma must be differentiated primarily from HCC that arises in metabolic diseases and some chronic liver diseases (eg, hereditary tyrosinemia, Alagille syndrome and other familial cholestatic syndromes, neurofibromatosis, ataxia-telangiectasia, Fanconi anemia). Cirrhosis and other risks factors are absent in patients with hepatoblastoma. (See  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism"</a> and  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Alagille syndrome'</a> and  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a> and  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis", section on 'Fanconi anemia'</a> and  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/139432.html" rel="external">"Alagille syndrome"</a>.)</p><p>Hepatoblastomas arise from primitive cells that have the potential to differentiate along several lines. As such, hepatoblastoma mimics the developing fetal and embryonal liver, and is composed of a variety of cell types, giving rise to a morphologically complex tumor, which may include fetal and/or embryonal hepatocytes and heterologous tissues including cartilage, bone, striated muscle fibers, and squamous epithelium.</p><p class="headingAnchor" id="H1048093982"><span class="h2">Gross pathology</span><span class="headingEndMark"> — </span>Hepatoblastomas often present as well circumscribed, thinly encapsulated, nodular, single or multiple lesions measuring up to 20 cm in diameter. The tumor has a variegated bulging cut surface with foci of necrosis and hemorrhage. When a mesenchymal component is present, such as bone or cartilage, the cut surface of the tumor is gritty with multiple white or slightly transparent speckles.</p><p class="headingAnchor" id="H1048093989"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Hepatoblastoma consists of malignant liver cells at various stages of maturation and a variable mesenchymal component. The epithelial component always predominates and consists of two types of cells: "embryonal"-type cells, which are small, basophilic, darkly stained with uniform, hyperchromatic nuclei and scanty cytoplasm, arranged in sheets, ribbons, rosettes, acini, or tubules; and "fetal"-type cells, resembling hepatocytes with central round to oval nuclei and abundant granular or clear cytoplasm depending on the amount of glycogen or fat  (<a class="graphic graphic_picture graphicRef97394" href="/d/graphic/97394.html" rel="external">picture 40</a>). The cells are larger, eosinophilic, and lighter stained than the embryonal-type cells and arranged in trabeculae or plates. They are separated by sinusoids and may form bile canaliculi. The variation of darker and lighter-stained cells is characteristic of hepatoblastoma. Extramedullary hematopoiesis is often present in the sinusoids. When the biopsy specimen is small and contains only fetal-type cells, the distinction from well-differentiated HCC may be difficult.</p><p>The presence of a mesenchymal component, most commonly osteoid tissue and rarely cartilage  (<a class="graphic graphic_picture graphicRef97394" href="/d/graphic/97394.html" rel="external">picture 40</a>), rhabdomyoblasts, or neural elements, rules out HCC. AFP is almost always demonstrable in the cytoplasm of the epithelial cell component by immunohistochemical staining.</p><p>Approximately 2 percent of hepatoblastomas are composed of small cell undifferentiated cells (small cell undifferentiated hepatoblastoma) [<a href="#rid104">104</a>], resembling a neuroblastoma or other small blue cell tumor. (See  <a class="medical medical_review" href="/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma", section on 'Pathology'</a>.)</p><p>This subtype was formerly referred as anaplastic hepatoblastoma. Small cell undifferentiated hepatoblastoma grows diffusely and is highly invasive. Rhabdoid differentiation may be encountered, resembling malignant extrarenal rhabdoid tumor. Immunostaining shows reactivity for cytokeratin (CK)8, occasionally for vimentin, and rarely for CD99. AFP immunostaining is generally negative.</p><p>Tumors composed of pure fetal cells carry a better prognosis than embryonal or mixed epithelial-mesenchymal hepatoblastomas or small cell undifferentiated hepatoblastoma [<a href="#rid105">105,106</a>].</p><p>An international consensus classification of hepatoblastoma has been proposed  (<a class="graphic graphic_table graphicRef97396" href="/d/graphic/97396.html" rel="external">table 4</a>) [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H1048093996"><span class="h1">MESENCHYMAL TUMORS</span></p><p class="headingAnchor" id="H1048094004"><span class="h2">Epithelioid hemangioendothelioma</span><span class="headingEndMark"> — </span>Epithelioid hemangioendothelioma (EHE) is a low-grade malignant vascular neoplasm that affects middle-aged patients. Women are affected more than men; there is a female predilection [<a href="#rid108">108,109</a>]. Most patients present with abdominal pain, a mass, weight loss, or malaise. Involvement of major hepatic veins may result in Budd-Chiari syndrome [<a href="#rid110">110</a>]. (See  <a class="medical medical_review" href="/d/html/3562.html" rel="external">"Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Imaging studies show single or multiple masses that are avascular or calcified and may involve the entire liver [<a href="#rid111">111</a>]. Despite being a low-grade tumor, there is a high rate of regional and distant metastases (75 percent in one study [<a href="#rid112">112</a>]).</p><p>EHE is typically a firm, tan tumor. It has a zonal pattern of cellularity; the periphery or the advancing front is more cellular than the central zone, which is hypocellular, sclerotic, or calcified; and the transition zone appears myxoid or cartilaginous. The underlying lobular architecture remains preserved with remnants of portal tracts. The tumor cells assume dendritic and epithelioid appearances [<a href="#rid113">113</a>]. The dendritic cells are spindle or stellate shaped. The epithelioid cells resemble signet rings  (<a class="graphic graphic_picture graphicRef97397" href="/d/graphic/97397.html" rel="external">picture 41</a>) with vessel-like intracellular lumen, which may contain red blood cells. Immunohistochemical staining shows positivity for vascular markers, such as the ERG transcription factor, CD31, CD34, and Factor VIII antigen [<a href="#rid114">114</a>].</p><p>EHE may be misdiagnosed as cholangiocarcinoma (CC) because of the epithelioid appearance and the sclerotic pattern of growth [<a href="#rid115">115</a>]. It should be noted, however, that the lumens of CC do not contain red blood cells, and markers for endothelial cells such as the ERG transcription factor, factor VIII–related antigen, CD31, and CD34 antigens are not demonstrable in CC [<a href="#rid108">108,110</a>].</p><p class="headingAnchor" id="H1048094011"><span class="h2">Angiosarcoma</span><span class="headingEndMark"> — </span>Angiosarcoma is a high-grade malignant vascular neoplasm [<a href="#rid116">116</a>], and it is the most common sarcoma arising in the liver [<a href="#rid117">117</a>]. It occurs in older patients (&gt;60 years old) and is more common in men. It can be caused by exposure to vinyl chloride [<a href="#rid118">118</a>], arsenic, anabolic steroids, radiation, and thorium dioxide. Patients typically present with abdominal pain, fatigue, jaundice, ascites, and weight loss. Rarely, patients present with Budd-Chiari syndrome. Hepatomegaly with or without splenomegaly and thrombocytopenia are common findings. Metastases occur frequently and rapidly to the spleen, lymph nodes, lung, bone, and adrenals [<a href="#rid112">112</a>]. Liver failure and intraabdominal bleeding due to liver rupture are common causes of death.</p><p>Angiosarcoma forms numerous poorly defined variably sized nodules that are soft, spongy, hemorrhagic, and necrotic. The entire liver is frequently involved. The tumor is composed of pleomorphic spindle or epithelioid cells, often with bizarre or multinucleated forms; mitoses are evident  (<a class="graphic graphic_picture graphicRef97398" href="/d/graphic/97398.html" rel="external">picture 42</a>). Better-differentiated areas may show large cavernous spaces that are lined by atypical endothelial cells. The tumor cells grow along and into sinusoids, peliotic areas, and branches of portal and hepatic veins. Immunostaining shows positivity for vascular markers, such as the ERG transcription factor, CD31, CD34, and Factor VIII antigen [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H2409303"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Several different types of primary tumors can arise in the liver, although metastases are more common by far. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common primary malignant liver tumor is hepatocellular carcinoma (HCC). HCC may form a large solitary circumscribed nodule with or without adjacent smaller satellite nodules. In the presence of cirrhosis, HCC may be multinodular within one lobe, consist of multiple nodules scattered throughout the liver, or infiltrate the liver diffusely without forming circumscribed nodules. The cells of HCC resemble hepatocytes in function, cytologic features, and growth patterns. The degree of differentiation reflects the resemblance of tumor cells to normal hepatocytes. Immunohistochemically, most well- to moderately well-differentiated HCCs are positive for hepatocyte paraffin 1 (HepPar1), arginase-1, cytoplasmic thyroid transcription factor-1 (TTF-1), glutamine synthetase, glypican-3 (GPC3), and cytokeratins (CK) 8 and 18. (See <a class="local">'Hepatocellular carcinoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fibrolamellar carcinoma differs clinically, histologically, and molecularly from conventional HCC. It affects younger individuals, is often not associated with elevated serum alpha-fetoprotein (AFP), and has a better prognosis than conventional HCC. The immunohistochemical profile is similar to that of HCC, such as positive staining for HepPar1 and GPC3. However, immunostains for CK7, epithelial membrane antigen (EMA), and cluster of differentiation (CD) 68 are positive in fibrolamellar carcinoma only. (See <a class="local">'Fibrolamellar subtype'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholangiocarcinomas (CCs) are primary cancers arising from bile duct epithelium that may occur anywhere along the biliary tree from the small bile ducts and bile ductules in the liver (intrahepatic CC) to the large hilar and extrahepatic bile ducts (extrahepatic CC). Immunohistochemistry can be very helpful for the differential diagnosis, which includes primary HCC and metastatic adenocarcinomas  (<a class="graphic graphic_table graphicRef97387" href="/d/graphic/97387.html" rel="external">table 2</a>). (See <a class="local">'Cholangiocarcinoma'</a> above.)</p><p></p><p class="bulletIndent1">Cholangiolocellular carcinoma (CCC) is a subtype of intrahepatic CC that is thought to originate from a hepatocyte progenitor cell, which can give rise to tumors with a whole range of phenotypes that have varying hepatocellular and cholangiocellular differentiation characteristics. (See <a class="local">'Cholangiolocellular carcinoma'</a> above.)</p><p></p><p class="bulletIndent1">Combined hepatocellular-cholangiocarcinoma is a tumor with intimately mixed elements of both HCC and CC; it must be distinguished from separate HCC and CC arising in the same liver lobe (which may be separated or intermixed ["collision" tumors]). They are classified, staged, and treated as intrahepatic CCs. (See <a class="local">'Combined hepatocellular-cholangiocarcinoma'</a> above.)</p><p></p><p class="bulletIndent1">There are three precursors to CC: intraductal papillary neoplasm of bile duct (IPNB), the rare intraductal tubulopapillary neoplasm of bile duct (ITPN), and the much more common biliary intraepithelial neoplasia (BilIN), which are divided into low- and high-grade types. When an invasive carcinoma is present, it should be separately designated and staged as CC. (See <a class="local">'Precursor (intraductal) lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The term mucinous cystic neoplasm of the liver (MCN) encompasses cystic tumors previously referred to as biliary cystadenoma and cystadenocarcinoma. However, the term cystadenocarcinoma has been used to designate high-grade MCN and MCN with an invasive component. The terms "MCN with high-grade intraepithelial neoplasia" and "MCN with an associated invasive carcinoma" are preferred [<a href="#rid99">99</a>]. (See <a class="local">'Mucinous cystic neoplasms (biliary cystadenoma and cystadenocarcinoma)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatoblastoma is the most common primary hepatic malignancy in early childhood. These tumors are thought to arise from primitive cells with the potential to differentiate along several lines. Hepatoblastomas mimic the developing fetal and embryonal liver and are composed of a variety of cell types, giving rise to a morphologically complex tumor that may include fetal and/or embryonal hepatocytes and heterologous tissues, including cartilage, bone, striated muscle fibers, and squamous epithelium. (See <a class="local">'Hepatoblastoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary mesenchymal tumors arising in the liver include epithelioid hemangioendothelioma (EHE) and angiosarcoma. Despite being a low-grade tumor, there is a high rate of regional and distant metastases with EHE. In contrast, angiosarcoma, the most common sarcoma arising in the liver, is a high-grade malignant vascular neoplasm. In both cases, immunostaining is positive for vascular markers such as the ERG transcription factor, CD31, CD34, and Factor VIII antigen. (See <a class="local">'Mesenchymal tumors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goodman ZD. Neoplasms of the liver. Mod Pathol 2007; 20 Suppl 1:S49.</a></li><li><a class="nounderline abstract_t">Quaglia A. Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist. J Hepatocell Carcinoma 2018; 5:99.</a></li><li><a class="nounderline abstract_t">Bickenbach K, Galka E, Roggin KK. Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma? Surg Oncol Clin N Am 2009; 18:215.</a></li><li><a class="nounderline abstract_t">Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131:1758.</a></li><li><a class="nounderline abstract_t">Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105:65.</a></li><li><a class="nounderline abstract_t">Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014; 27:420.</a></li><li><a class="nounderline abstract_t">Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 2019; 17:748.</a></li><li class="breakAll">Torbenson MS, Ng IOL, Park YN, et al. Hepatocellular carcinoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.228.</li><li class="breakAll">Sempoux C, Kakar S, Kondo F, Schirmacher P. Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th, Arends MJ, Fukuyama M, Klimstra DS, et al (Eds), IARC, Lyon 2019. p.260.</li><li class="breakAll">Eggel H. Uber das primare Carcinom der Leber. Beitr z path Anat z allg Path 1910; 3:5060.</li><li><a class="nounderline abstract_t">Okuda K, Peters RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984; 54:2165.</a></li><li class="breakAll">Nakashima T, Kojiro M. Hepatocellular carcinoma. In: An atlas of its pathology, Springer-Verlag, Tokyo 1987.</li><li><a class="nounderline abstract_t">Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693.</a></li><li><a class="nounderline abstract_t">Plessier A, Codes L, Consigny Y, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10:S86.</a></li><li><a class="nounderline abstract_t">D'Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15:1278.</a></li><li><a class="nounderline abstract_t">Jonas S, Bechstein WO, Steinmüller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080.</a></li><li><a class="nounderline abstract_t">Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009; 137:850.</a></li><li><a class="nounderline abstract_t">Lauwers GY, Vauthey JN. Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. Hepatogastroenterology 1998; 45 Suppl 3:1197.</a></li><li><a class="nounderline abstract_t">Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 2013; 82:e212.</a></li><li><a class="nounderline abstract_t">Tacher V, Lin M, Duran R, et al. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology 2016; 278:275.</a></li><li><a class="nounderline abstract_t">Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol 2002; 26:25.</a></li><li><a class="nounderline abstract_t">Ziol M, Poté N, Amaddeo G, et al. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018; 68:103.</a></li><li><a class="nounderline abstract_t">Farooq A, Merath K, Paredes AZ, et al. Outcomes of Patients with Scirrhous Hepatocellular Carcinoma: Insights from the National Cancer Database. J Gastrointest Surg 2020; 24:1049.</a></li><li><a class="nounderline abstract_t">Wu L, Tsilimigras DI, Farooq A, et al. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis. Cancer 2019; 125:3767.</a></li><li><a class="nounderline abstract_t">Lv TR, Hu HJ, Regmi P, et al. Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2022; 148:1685.</a></li><li><a class="nounderline abstract_t">International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983.</a></li><li><a class="nounderline abstract_t">Le Bail B, Bernard PH, Carles J, et al. Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J Hepatol 1997; 27:835.</a></li><li><a class="nounderline abstract_t">Deugnier YM, Charalambous P, Le Quilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 1993; 18:1363.</a></li><li><a class="nounderline abstract_t">Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997; 26:1415.</a></li><li><a class="nounderline abstract_t">Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001; 39:66.</a></li><li><a class="nounderline abstract_t">Koo JS, Kim H, Park BK, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B. J Clin Gastroenterol 2008; 42:738.</a></li><li><a class="nounderline abstract_t">Nam SW, Park JY, Ramasamy A, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005; 42:809.</a></li><li><a class="nounderline abstract_t">Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25:133.</a></li><li><a class="nounderline abstract_t">Efremidis SC, Hytiroglou P, Matsui O. Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol 2007; 17:2969.</a></li><li><a class="nounderline abstract_t">Rudini N, Novello C, Destro A, et al. Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications. Histopathology 2018; 73:601.</a></li><li><a class="nounderline abstract_t">Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006; 50:257.</a></li><li><a class="nounderline abstract_t">Lin F, Abdallah H, Meschter S. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver. Diagn Cytopathol 2004; 30:92.</a></li><li><a class="nounderline abstract_t">Lei JY, Bourne PA, diSant'Agnese PA, Huang J. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol 2006; 125:519.</a></li><li><a class="nounderline abstract_t">Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16.</a></li><li><a class="nounderline abstract_t">Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88:78.</a></li><li><a class="nounderline abstract_t">Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30:17.</a></li><li><a class="nounderline abstract_t">Saad RS, Luckasevic TM, Noga CM, et al. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004; 30:1.</a></li><li><a class="nounderline abstract_t">Nguyen T, Phillips D, Jain D, et al. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma. Arch Pathol Lab Med 2015; 139:1028.</a></li><li><a class="nounderline abstract_t">Shah SS, Wu TT, Torbenson MS, Chandan VS. Aberrant CDX2 expression in hepatocellular carcinomas: an important diagnostic pitfall. Hum Pathol 2017; 64:13.</a></li><li><a class="nounderline abstract_t">Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45:725.</a></li><li><a class="nounderline abstract_t">Park YN, Kojiro M, Di Tommaso L, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 2007; 109:915.</a></li><li><a class="nounderline abstract_t">Yoneda N, Sato Y, Kitao A, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest 2011; 91:262.</a></li><li><a class="nounderline abstract_t">Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94:851.</a></li><li><a class="nounderline abstract_t">Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49:138.</a></li><li><a class="nounderline abstract_t">Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011; 54:1707.</a></li><li><a class="nounderline abstract_t">Lai JP, Conley A, Knudsen BS, Guindi M. Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma. Histopathology 2015; 67:442.</a></li><li><a class="nounderline abstract_t">Zen C, Zen Y, Mitry RR, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 2011; 17:943.</a></li><li><a class="nounderline abstract_t">Calderaro J, Meunier L, Nguyen CT, et al. ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. Clin Cancer Res 2019; 25:5859.</a></li><li><a class="nounderline abstract_t">Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44:694.</a></li><li><a class="nounderline abstract_t">Nault JC, Calderaro J, Di Tommaso L, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014; 60:1983.</a></li><li><a class="nounderline abstract_t">Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017; 67:727.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Research Network. Electronic address: <span class="__cf_email__" data-cfemail="14637c7171787166547677793a717061">[email protected]</span>, Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017; 169:1327.</a></li><li><a class="nounderline abstract_t">Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47:505.</a></li><li><a class="nounderline abstract_t">Zhao LH, Liu X, Yan HX, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 2016; 7:12992.</a></li><li><a class="nounderline abstract_t">Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology 2017; 153:812.</a></li><li><a class="nounderline abstract_t">El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017; 389:2492.</a></li><li><a class="nounderline abstract_t">Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011; 31:61.</a></li><li><a class="nounderline abstract_t">Li W, Tan D, Zenali MJ, Brown RE. Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 2009; 3:238.</a></li><li><a class="nounderline abstract_t">Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 2014; 343:1010.</a></li><li><a class="nounderline abstract_t">Ward SC, Huang J, Tickoo SK, et al. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010; 23:1180.</a></li><li><a class="nounderline abstract_t">Ross HM, Daniel HD, Vivekanandan P, et al. Fibrolamellar carcinomas are positive for CD68. Mod Pathol 2011; 24:390.</a></li><li><a class="nounderline abstract_t">Kim YJ, Rhee H, Yoo JE, et al. Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma. Histopathology 2017; 71:217.</a></li><li><a class="nounderline abstract_t">Cornella H, Alsinet C, Sayols S, et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology 2015; 148:806.</a></li><li><a class="nounderline abstract_t">Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol 2015; 28:822.</a></li><li><a class="nounderline abstract_t">Xu L, Hazard FK, Zmoos AF, et al. Genomic analysis of fibrolamellar hepatocellular carcinoma. Hum Mol Genet 2015; 24:50.</a></li><li><a class="nounderline abstract_t">Sempoux C, Jibara G, Ward SC, et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis 2011; 31:49.</a></li><li><a class="nounderline abstract_t">Hayashi A, Misumi K, Shibahara J, et al. Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma. Am J Surg Pathol 2016; 40:1021.</a></li><li><a class="nounderline abstract_t">Chan ES, Yeh MM. The use of immunohistochemistry in liver tumors. Clin Liver Dis 2010; 14:687.</a></li><li><a class="nounderline abstract_t">Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 2012; 7:149.</a></li><li><a class="nounderline abstract_t">Al-Muhannadi N, Ansari N, Brahmi U, Satir AA. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material. Ann Hepatol 2011; 10:508.</a></li><li><a class="nounderline abstract_t">Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012; 55:1876.</a></li><li><a class="nounderline abstract_t">Matsuda M, Hara M, Suzuki T, et al. Synchronously resected double primary hepatic cancers - hepatocellular carcinoma and cholangiolocellular carcinoma. J Hepatobiliary Pancreat Surg 2006; 13:571.</a></li><li><a class="nounderline abstract_t">Shiota K, Taguchi J, Nakashima O, et al. Clinicopathologic study on cholangiolocellular carcinoma. Oncol Rep 2001; 8:263.</a></li><li><a class="nounderline abstract_t">Sempoux C, Fan C, Singh P, et al. Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis 2011; 31:104.</a></li><li><a class="nounderline abstract_t">Kanamoto M, Yoshizumi T, Ikegami T, et al. Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver:a case report. J Med Invest 2008; 55:161.</a></li><li><a class="nounderline abstract_t">Moeini A, Sia D, Zhang Z, et al. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017; 66:952.</a></li><li><a class="nounderline abstract_t">Theise ND, Yao JL, Harada K, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003; 43:263.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010; 2:419.</a></li><li><a class="nounderline abstract_t">Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37:496.</a></li><li><a class="nounderline abstract_t">Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 2018; 68:113.</a></li><li><a class="nounderline abstract_t">Schlitter AM, Born D, Bettstetter M, et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 2014; 27:73.</a></li><li><a class="nounderline abstract_t">Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20:701.</a></li><li><a class="nounderline abstract_t">Zen Y, Sasaki M, Fujii T, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 2006; 44:350.</a></li><li><a class="nounderline abstract_t">Sato Y, Harada K, Sasaki M, Nakanuma Y. Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma. Virchows Arch 2013; 462:421.</a></li><li class="breakAll">Basturk O. Aishima S, Esposito I. Biliary intraepithelial neoplasia. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.273.</li><li><a class="nounderline abstract_t">Nakanuma Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int 2010; 60:419.</a></li><li><a class="nounderline abstract_t">Zen Y, Fujii T, Itatsu K, et al. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 2006; 44:1333.</a></li><li><a class="nounderline abstract_t">Nakanishi Y, Zen Y, Hirano S, et al. Intraductal oncocytic papillary neoplasm of the bile duct: the first case of peribiliary gland origin. J Hepatobiliary Pancreat Surg 2009; 16:869.</a></li><li><a class="nounderline abstract_t">Nakanuma Y, Kakuda Y, Uesaka K. Characterization of Intraductal Papillary Neoplasm of the Bile Duct with Respect to the Histopathologic Similarities to Pancreatic Intraductal Papillary Mucinous Neoplasm. Gut Liver 2019; 13:617.</a></li><li><a class="nounderline abstract_t">Nanashima A, Kinoshita N, Nakanuma Y, et al. Clinicopathological features of "intraductal papillary neoplasm of the bile duct" and patient outcome after surgical resection. Hepatogastroenterology 2008; 55:1167.</a></li><li><a class="nounderline abstract_t">Fukumura Y, Nakanuma Y, Kakuda Y, et al. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes. Virchows Arch 2017; 471:65.</a></li><li class="breakAll">Nakanuma Y, Basturk O, Esposito I, et al. Intraductal papillary neoplasm of the bile ducts. In: WHO Classification of Tumours: Digestive System Tumours, 5th, Arends MJ, Fukuyama M, Klimstra DS, et al (Eds), IARC, Lyon 2019. p.279.</li><li><a class="nounderline abstract_t">Schlitter AM, Jang KT, Klöppel G, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol 2015; 28:1249.</a></li><li class="breakAll">Basturk O, Nakanuma Y, Aishima S, et al. Mucinous cystic neoplasm of the liver and biliary system. In: WHO Classification of Tumours: Digestive System Tumours, 5th, Arends MJ, Fukuyama M, Klimstra DS, et al (Eds), IARC, Lyon 2019. p.250.</li><li><a class="nounderline abstract_t">Buetow PC, Buck JL, Pantongrag-Brown L, et al. Biliary cystadenoma and cystadenocarcinoma: clinical-imaging-pathologic correlations with emphasis on the importance of ovarian stroma. Radiology 1995; 196:805.</a></li><li><a class="nounderline abstract_t">Abdul-Al HM, Makhlouf HR, Goodman ZD. Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study. Virchows Arch 2007; 450:691.</a></li><li class="breakAll">Saxena R, Quaglia A. Hepatoblastoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, Arends MJ, Fukuyama M, Klimstra DS, et al (Eds), IARC, Lyon 2019. p.240.</li><li><a class="nounderline abstract_t">Kamien BA, Gabbett MT. Aicardi syndrome associated with hepatoblastoma and pulmonary sequestration. Am J Med Genet A 2009; 149A:1850.</a></li><li><a class="nounderline abstract_t">Gonzalez-Crussi F. Undifferentiated small cell ("anaplastic") hepatoblastoma. Pediatr Pathol 1991; 11:155.</a></li><li><a class="nounderline abstract_t">von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 1997; 74:593.</a></li><li><a class="nounderline abstract_t">Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53:1016.</a></li><li><a class="nounderline abstract_t">Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26:19.</a></li><li><a class="nounderline abstract_t">Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999; 85:562.</a></li><li><a class="nounderline abstract_t">Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107:2108.</a></li><li><a class="nounderline abstract_t">Walsh MM, Hytiroglou P, Thung SN, et al. Epithelioid hemangioendothelioma of the liver mimicking Budd-Chiari syndrome. Arch Pathol Lab Med 1998; 122:846.</a></li><li><a class="nounderline abstract_t">den Bakker MA, den Bakker AJ, Beenen R, et al. Subtotal liver calcification due to epithelioid hemangioendothelioma. Pathol Res Pract 1998; 194:189.</a></li><li><a class="nounderline abstract_t">Groeschl RT, Miura JT, Oshima K, et al. Does histology predict outcome for malignant vascular tumors of the liver? J Surg Oncol 2014; 109:483.</a></li><li><a class="nounderline abstract_t">Ishak KG, Sesterhenn IA, Goodman ZD, et al. Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases. Hum Pathol 1984; 15:839.</a></li><li><a class="nounderline abstract_t">Antonescu C. Malignant vascular tumors--an update. Mod Pathol 2014; 27 Suppl 1:S30.</a></li><li><a class="nounderline abstract_t">Ferrell L. Malignant liver tumors that mimic benign lesions: analysis of five distinct lesions. Semin Diagn Pathol 1995; 12:64.</a></li><li><a class="nounderline abstract_t">Suriawinata AA, Thung SN. Malignant liver tumors. Clin Liver Dis 2002; 6:527.</a></li><li><a class="nounderline abstract_t">Bioulac-Sage P, Laumonier H, Laurent C, et al. Benign and malignant vascular tumors of the liver in adults. Semin Liver Dis 2008; 28:302.</a></li><li><a class="nounderline abstract_t">Sherman M. Vinyl chloride and the liver. J Hepatol 2009; 51:1074.</a></li></ol></div><div id="topicVersionRevision">Topic 16348 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486052" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neoplasms of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30519546" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306808" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular mechanisms of cholangiocarcinogenesis: are biliary intraepithelial neoplasia and intraductal papillary neoplasms of the bile duct precursors to cholangiocarcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17087938" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561091" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24051694" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908364" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908364" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908364" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29908364" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091861" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091861" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8594428" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762846" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19790142" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343235" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19524573" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730374" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23332890" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26131913" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756766" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29281854" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31243715" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcomes of Patients with Scirrhous Hepatocellular Carcinoma: Insights from the National Cancer Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31299092" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35201426" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657307" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Terminology of nodular hepatocellular lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382971" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7902316" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9397980" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11454046" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277883" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175600" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15918142" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early hepatocellular carcinoma and dysplastic nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618439" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791027" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phenotypic and molecular changes in nodule-in-nodule hepatocellular carcinoma with pathogenetic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16780018" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14755758" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16627262" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788060" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18026163" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20175030" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14696137" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26230595" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28089540" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aberrant CDX2 expression in hepatocellular carcinomas: an important diagnostic pitfall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326147" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17279586" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20856226" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556657" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16879391" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045674" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425262" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491582" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31358545" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561517" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25123086" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28532995" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28622513" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25822088" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27703150" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624577" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28434648" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344351" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20224721" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24578576" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495535" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21113139" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fibrolamellar carcinomas are positive for CD68.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28326574" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tumour epithelial and stromal characteristics of hepatocellular carcinomas with abundant fibrous stroma: fibrolamellar versus scirrhous hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557953" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Unique genomic profile of fibrolamellar hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25698061" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : DNAJB1-PRKACA is specific for fibrolamellar carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122662" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Genomic analysis of fibrolamellar hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344350" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intrahepatic cholangiocarcinoma: new insights in pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27259014" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055690" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The use of immunohistochemistry in liver tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23111165" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911893" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271564" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17139434" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Synchronously resected double primary hepatic cancers - hepatocellular carcinoma and cholangiolocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11182037" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinicopathologic study on cholangiolocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21344355" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319561" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cholangiolocellular carcinoma containing hepatocellular carcinoma and cholangiocellular carcinoma, extremely rare tumor of the liver:a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28126467" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940779" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hepatic 'stem cell' malignancies in adults: four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191517" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388123" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360137" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828315" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431410" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360234" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446751" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446751" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20518896" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17058219" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19322511" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Intraductal oncocytic papillary neoplasm of the bile duct: the first case of peribiliary gland origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982236" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Characterization of Intraductal Papillary Neoplasm of the Bile Duct with Respect to the Histopathologic Similarities to Pancreatic Intraductal Papillary Mucinous Neoplasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18795651" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinicopathological features of "intraductal papillary neoplasm of the bile duct" and patient outcome after surgical resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550497" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550497" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111977" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111977" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644647" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Biliary cystadenoma and cystadenocarcinoma: clinical-imaging-pathologic correlations with emphasis on the importance of ovarian stroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457606" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457606" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Expression of estrogen and progesterone receptors and inhibin-alpha in hepatobiliary cystadenoma: an immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19610089" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Aicardi syndrome associated with hepatoblastoma and pulmonary sequestration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849636" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Undifferentiated small cell ("anaplastic") hepatoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9421354" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prognostic factors and staging systems in childhood hepatoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588519" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24322718" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10091730" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17019735" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740148" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Epithelioid hemangioendothelioma of the liver mimicking Budd-Chiari syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9587938" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Subtotal liver calcification due to epithelioid hemangioendothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284733" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Does histology predict outcome for malignant vascular tumors of the liver?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6088383" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24384851" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Malignant vascular tumors--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7770675" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Malignant liver tumors that mimic benign lesions: analysis of five distinct lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12122869" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Malignant liver tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814083" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Benign and malignant vascular tumors of the liver in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19836850" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Vinyl chloride and the liver.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
